Sun Valley Arthritis Center — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$338,133	12
2024	Research	$229,262	11
2023	Research	$82,099	35
2022	Research	$46,339	46
2021	Research	$23,575	9
2020	Research	$27,908	17
2019	Research	$20,166	20

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $603,809 10 payments
AbbVie, Inc. $93,689 91 payments
Hexal AG $55,195 44 payments
GlaxoSmithKline, LLC. $12,000 3 payments
Amgen Inc. $1,790 1 payment
Celgene Corporation $1,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) $284,756 2 payments
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) $267,289 3 payments
Cgp24112301 $55,195 44 payments
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $37,863 37 payments
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL $37,414 2 payments
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy $18,021 17 payments
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) $17,237 15 payments
A Phase III Randomized Double Blind Placebo Controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy Safety and Tolerability Up to 5 Years in Patients With $11,251 1 payment
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs $7,415 11 payments
A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $4,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.